Species-specific susceptibility to cannabis-induced convulsions

Downloads

Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, et al. (2017). The concise guide to pharmacology: G protein-coupled receptors. Br J Pharmacol 174: S17-S129. Bertram E (2007). The relevance of kindling for human epilepsy. Epilepsia 48: 65-74. Black JW, Leff P (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014). Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144: 12-41. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR (1996). Toxicity and carcinogenicity of 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30: 109-117. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 219: 859-873. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C et al. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55: 791-802. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al.; Cannabidiol in Dravet Syndrome Study Group (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engll J Med 376: 2011-2020. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J et al. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15: 270-278. Devinsky O, Whalley BJ, Di Marzo V (2015). Cannabinoids in the treatment of neurological disorders. Neurotherapeutics 12: 689-691. Diana MA, Marty A (2004). Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 142: 9-19. Fitzgerald KT, Bronstein AC, Newquist KL (2013). Marijuana poisoning. Top Companion Anim Med 28: 8-12. Gurney SM, Scott KS, Kacinko SL, Presley BC, Logan BK (2014). Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26: 53-78. Guy GW, Robson P (2003). A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 difference areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J Cannabis Ther 3: 79-120. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091-D1106. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87: 1932-1936. Heske L, Nødtvedt A, Jäderlund KH, Berendt M, Egenvall A (2014). A cohort study of epilepsy among 665,000 insured dogs: incidence, mortality and survival after diagnosis. Vet J 202: 471-476. Hill AJ, Williams CM, Whalley BJ, Stephens GJ (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 133: 79-97. Jones NA, Glyn SE, Akiyama S, Hill TDM, Hill AJ, Weston SE et al. (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure-Eur J Epilepsy 21: 344-352. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ et al. (2010). Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 332: 569-577. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011). Plasma cannabinoid pharmacokinetics following controlled oral Δ9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57: 66-75. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172: 4790-4805. Lee D, Bergamaschi MM, Milman G, Barnes AJ, Queiroz RH, Vandrey R et al. (2015). Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users. J Anal Toxicol 39: 580-587. Lemberger L, Martz R, Rodda B, Forney R, Rowe H (1973). Comparative pharmacology of 9-tetrahydrocannabinol and its metabolite, 11-OH- 9-tetrahydrocannabinol. J Clin Invest 52: 2411-2417. Luttjohann A, Fabene PF, van Luijtelaar G (2009). A revised Racine's scale for PTZ-induced seizures in rats. Physiol Behav 98: 579-586. Mastropaolo J, Rosse RB, Deutsch SI (2004). Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia. Behav Brain Res 153: 419-422. McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015). Are cannabidiol and 9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172: 737-753. McPartland JM, Glass M, Pertwee RG (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 152: 583-593. Murphy M, Mills S, Winstone J Leishman E, Wager-Miller J, Bradshaw H et al. (2017). Chronic adolescent Δ9-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis and Cannabinoid Res 2: 235-246. NTP (1996). National Toxicology Program - toxicology and carcinogenesis studies of 1-trans- 9-tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 446: 1-317. Press CA, Knupp KG, Chapman KE (2015). Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 45: 49-52. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O (2015). Cannabinoids and epilepsy. Neurotherapeutics 12: 747-768. Rosenberg EC, Patra PH, Whalley BJ (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav 70: 319-327. Sharma P, Murthy P, Bharath MM (2012). Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 7: 149-156. Silva L, Black R, Michaelides M, Hurd YL, Dow-Edwards D (2016). Sex and age specific effects of 9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal. Neurotoxicol Teratol 58: 88-100. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411. Volkow ND, Baler RD, Compton WM, Weiss SR (2014). Adverse health effects of marijuana use. N Engl J Med 370: 2219-2227. Wolfensohn S, Lloyd M (2013). Handbook of Laboratory Animal Management and Welfare. Wiley & Sons, Oxford.